The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · May 16, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different brain processes affect a person's ability to speak and generate words quickly, especially after brain injuries like strokes or neurodegenerative diseases. Researchers want to understand whether difficulties in verbal fluency come from problems with planning and organizing thoughts (executive functions) or from language skills themselves. By exploring these connections, the trial aims to identify which areas of the brain are involved and improve how we diagnose and treat these communication issues.
To participate in this study, candidates must be between 40 and 85 years old, speak French, and have some form of cognitive impairment due to a neurodegenerative disease or have had a stroke. Participants will undergo tests that assess their verbal skills and cognitive functions. This research could lead to better understanding and support for people facing challenges with speech and language after brain injuries. It’s important to note that certain medical conditions or treatments may exclude individuals from participating in the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • For Cognitive cortical neurodegenerative diseases PATIENTS
- • informed consentPatients between 40 and 85 years old,
- • French native language,
- • Social Security affiliation,
- • Can read, write and count (up to 36) and knows the alphabet
- * Assessed in Amiens University Memory Clinic for:
- * Mild severity impairment (MMSE\> 19) or major severity impairment related to:
- • AD according to Albert criteria and McKhann criteria
- • DCL according to McKeith criteria
- • FTLD according to Rascovsky criteria
- • CBD according to Armstrong's criteria
- • PSP according to Höglinger criteria
- • For Stroke PATIENTS
- • informed consent
- • Patients between 40 and 85 years old,
- • French native language,
- • Social Security affiliation,
- • Can read, write and count (up to 36) and knows the alphabet
- • Having suffered a stroke, hospitalized in neurology, visualized by imaging
- Exclusion Criteria:
- • Mental retardation or guardianship
- * Other current or past brain condition affecting cognition, including:
- • Severe head trauma
- • Epilepsy prior to stroke still requiring previous treatment
- • Parkinson disease, multiple sclerosis
- • Brain tumor or brain radiation therapy
- • Current or past schizophrenia or psychosis
- • Active or past psychiatric impairments requiring a stay\> 2 days in a specialized environment
- • Contra indication to MRI
- • Comorbidity with life expectancy \<1 year
- * Comorbidity affecting cognition in particular:
- • Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
- • Opiate or cocaine addiction or opiate withdrawal syndrome
- • Renal failure (dialysis or creatinine clearance \<30)
- • Hepatic failure (spontaneous INR\> 1.5 or PT \<60%)
- • Respiratory failure requiring oxygen therapy
- • Heart failure (orthopnea\> 2 pillows)
- • Persistent vigilance disorder (NIHSS1a score ≤1)
- • Cancer with paraneoplastic syndrome
- • Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
- • Patient under guardianship or curators or private under public law
- • Pregnant and / or lactating woman
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported